Breast implant safety in Brazil: Anvisa records and long-term follow-up

Breast implant safety involves the device, the operation and continuing care over time. In Brazil, Anvisa registration is an important product check, but it does not guarantee that a device will last forever or that surgery will have no complications. An overseas patient also needs usable implant records and a follow-up plan that remains practical after returning home. These considerations belong in the decision before an operation, not only when a problem occurs years later.

The aim is to understand what is being proposed and how to keep track of it. You do not need to choose a brand from internet rankings or diagnose a device problem yourself. The breast surgery comparison guide provides context for deciding whether an implant is relevant to your goals in the first place. Registration, a suitable clinical indication, informed consent and continuity of care answer different questions; none should be treated as a substitute for the others.

What does Anvisa registration mean?

Anvisa is Brazil's national health regulatory agency. When an implant is proposed, ask for the exact product identity and how its current status in Brazil can be verified. Check the actual manufacturer and model rather than relying on a generic statement that a clinic uses “approved silicone”. The agency's patient guidance on device traceability emphasizes retaining product information, including for breast implants.

A regulatory status concerns a product in a particular jurisdiction. It is not an international credential for the surgeon, an endorsement of a hospital or proof that the product is the best choice for your anatomy. Do not translate Brazilian registration into US FDA approval or assume that a product accepted in one country has the same authorization or availability elsewhere. If cross-border device support matters to you, ask the relevant manufacturer or regulator about the actual product.

When someone uses the word “certified”, ask what is certified, by whom and for what purpose. The answer may concern a device, a professional qualification or a facility, each with different meaning. A useful explanation should identify the item being checked and let you verify it. If the discussion returns only to promotional descriptions without the information requested, obtain clarification before treating a quality claim as established fact.

Which device identification details should I receive?

Ask how you will receive the manufacturer, product model, size or volume, surface information and relevant lot or serial identifiers for each implant. The record should make clear which device is on which side and when it was inserted. Retain the device labels or card alongside the operative report. If you later have replacement or removal, preserve the earlier records as part of the history rather than discarding them when the new document arrives.

Separate the device identity from the details of the operation. A card may identify the implant without explaining its position, the incision or any additional breast reshaping. The operative report supplies different information. Ask which documents you will be given, when they become available and what information a clinician at home would need. A document's practical value depends on being legible, complete and easy to connect with the correct operation.

Before leaving, review the records for obvious administrative gaps: your identity, date, side and documents referred to but not included. Ask the provider to clarify an inconsistency rather than correcting medical details yourself. Keep the original wording of product names and identifiers even if other text is translated. A brand name rendered differently by a translation tool could make a later alert or replacement enquiry harder to interpret.

For a replacement operation, ask how the documents distinguish the device removed from the one inserted. A folder containing two different implant cards can become confusing unless each is attached to the correct date and side. Include any report about the reason for removal and relevant tissue findings. This is particularly useful if you later contact a manufacturer or clinician who did not participate in either operation and needs to reconstruct the history from the documents alone.

How can I retain useful records after returning home?

Keep a secure digital copy and the originals in a place you can find years later. Store clear images of labels rather than a blurred photograph that becomes unreadable when enlarged. Organize the files by date and operation, including any subsequent investigations. You can keep a short index stating where the full documents are stored, so that a future clinician does not have to search a large archive to identify the current implant.

Tell the clinicians responsible for your breast care about implants and previous surgery. Share the actual documents when relevant, with your consent, rather than relying on memory of a volume or a surgical term. If a report needs translation, ask which format is useful and retain the original beside it. An English-language article does not confirm that a practice will supply translated clinical records or conduct consultations in English; those arrangements need direct confirmation.

Plan for changes in contact details too. A device may remain in place after you change country, email address or healthcare provider. Ask how the manufacturer or provider communicates relevant product information and how your details can be updated where appropriate. Do not send personal health information to an unverified contact found in a social-media message. Use the organization's confirmed channel and keep a record of an important enquiry and response.

What does long-term safety monitoring tell us?

Anvisa's breast implant technovigilance bulletin describes monitoring of reported problems. Such reporting helps identify and investigate possible device concerns. However, spontaneous reports are not the same as a study following every implant user. They cannot establish the proportion of all patients who experience a complication, compare the safety of entire countries or prove that a device caused an individual's illness.

When reading a headline about reports, look for the population, the period covered and what the number actually counts. A report may describe a suspected event rather than an established diagnosis. An increase can have several explanations, including changes in awareness and reporting. A careful source explains these limits. Avoid treating a large total as your personal risk or a small total as proof that monitoring is unnecessary.

For your own care, ask what information is relevant to the exact device and your medical history. It may include the manufacturer's current patient information, product-specific alerts and the examining clinician's findings. Keeping records supports that discussion without requiring you to interpret every technical notice alone. An online article is a starting point for questions; it cannot establish the condition of the implant currently in your breast.

Do all implants need replacement at a fixed age?

No single anniversary decides replacement for every patient. Implants are not guaranteed lifetime devices, and further surgery may become necessary, but a fixed “replace at ten years” rule is not an individualized plan. The US FDA's information on implant risks discusses rupture, capsular contracture and possible reoperations. It is US regulatory information, not a personal Brazilian follow-up instruction or a guarantee that a particular device is authorized there.

Ask the clinician how your device, symptoms, examination and previous test findings inform the recommendation. A proposal to observe should explain how follow-up will work and which changes require earlier attention. A proposal for exchange or removal should identify the problem being addressed and the reasonable alternatives. The age of an implant is useful history, but is only one part of that assessment.

A general imaging timetable found online may apply to a particular regulator's advice or a manufacturer's labelling. Ask which guidance is relevant to your device and circumstances and how it will be followed where you live. Do not treat this article as a reason to order scans yourself or cancel a planned examination. The important goal is an understandable, feasible surveillance plan with a clinician who can interpret findings and respond when necessary.

Which new breast changes should prompt professional assessment?

Persistent swelling, a new lump, new pain or a significant change in one breast deserves assessment, even when an implant has been present for years. The cause cannot be diagnosed from a photograph or a message. Rare implant-associated conditions need appropriate investigation, while many other explanations are possible. Tell the clinician about the device and bring relevant records; do not assume either that every change is dangerous or that an old implant explains it automatically.

A 2025 Brazilian case series on implant-associated anaplastic large cell lymphoma highlights the importance of recognizing changes and obtaining the right diagnostic assessment. It is a selected report of affected patients, not an estimate of risk among all implant users. BIA-ALCL is a lymphoma associated with the implant environment, distinct from ordinary breast cancer. Its investigation and treatment belong with an appropriately qualified medical team.

The FDA's BIA-ALCL questions and answers identifies persistent swelling, a mass or pain as symptoms to discuss and explains that risk differs by implant surface history. It does not recommend automatic removal in every person without symptoms because of this concern. If you are worried, seek a personal discussion of the device and your circumstances rather than arranging preventive surgery solely from a headline.

How is implant surveillance different from breast cancer screening?

They address different questions. A clinician may investigate implant integrity, assess a particular symptom or recommend screening based on breast cancer risk. One examination does not automatically answer all three. INCA's public guidance distinguishes screening in people without suspicious symptoms from diagnostic investigation. A new breast change should be assessed without waiting for the next routine screening date.

Tell the imaging service about implants and previous operations before an examination, and provide relevant prior images when requested. Ask what the current test is intended to answer and who will review its result. If you receive several reports from different services or countries, keep them in date order. A short translated conclusion may not contain all the information needed for a clinician to compare findings over time.

Discuss your individual risk and the guidance relevant where you receive ongoing care. Family history, symptoms and previous findings may change the questions that need answering. Avoid using an age threshold from population guidance as a reason to dismiss a symptom or as a mandatory preoperative test list for every person. The role of evidence is to support appropriate assessment, not replace it with a one-size-fits-all checklist.

What should I do if I hear about an alert or recall?

First, establish whether it concerns the exact product you have, not simply a similar brand name or the general category of silicone implants. Locate the official notice and discuss it with a qualified clinician, using your device records. Read what action the notice actually recommends and who it addresses. A restriction on supply, a product investigation and advice for an implanted patient are not necessarily identical messages.

If you cannot identify your implant, request the original records and explain the uncertainty to the clinician. Do not assume the device is safe or affected solely because of the operation date. Ask which information is missing, what can reasonably be established and what assessment is appropriate. If you have symptoms, the need for clinical evaluation should not wait for every administrative question about the device to be answered.

Keep a copy of the notice and any advice received, including its date. Information can change as an investigation develops. Avoid forwarding a dramatic summary as though it were a personal instruction for everyone with implants. A useful discussion asks whether the notice changes your present plan and why. It should leave you with an appropriate next step rather than an unexplained choice between panic and doing nothing.

When discussing an alert, you can ask the clinician to separate three questions: whether your device is included, whether you have a clinical concern that needs investigation, and whether the notice changes the recommended follow-up. Those answers may involve different information. Keeping them separate helps avoid interpreting a product notice as a diagnosis or dismissing symptoms because the device is not named. Retain the response with the other device records so that a later clinician can understand what advice was given.

Which alternatives, including no operation, should I consider?

Before a first implant operation, ask whether your main concern is volume, position or breast weight. The augmentation guide and comparison of lifts with and without implants explain different starting points. You may decide the expected benefit does not justify having a device and accepting future monitoring or possible further surgery.

If you already have implants, options may include an agreed observation plan, further investigation, exchange or removal, depending on the findings. The explant assessment guide helps prepare questions about removal. A choice made for personal preference still deserves a clear explanation of surgical risks and shape changes. A medical concern may require a different pathway from an elective request for a different appearance.

If you are comparing the value of having an implant with an alternative that uses no device, include your own willingness and ability to maintain records and attend appropriate assessments over time. That commitment may affect the decision even when an initial operation is affordable. Ask what costs are predictable, which depend on future findings and how follow-up can be arranged where you expect to live. A plan should fit your circumstances without assuming that you will always be able to return to the same city.

How does living abroad affect the follow-up and quotation I need?

Ask which early visits require attendance in Santos, how findings and device records will be supplied and who can assess you after departure. Confirm the language, format and availability of communication rather than assuming them. The international follow-up handover guide helps make those responsibilities explicit. Routine contact arrangements should be distinguished from urgent care; serious or rapidly worsening symptoms require prompt medical attention where you are.

Request a personal itemized quotation for the proposed operation and ask what the device-related items cover. Clarify tests, appointments, possible further treatment and any exclusions. Add your own travel, accommodation, assistance and contingency costs. A manufacturer warranty, if offered, should be read for its actual terms rather than assumed to cover another operation, hospital charges or an international trip. No specific warranty or price is promised here.

An enquiry to Dra. Flávia Pacheco's practice in Santos can ask what assessment is available and what records are needed for a personalized plan. Before deciding, aim to understand the purpose of the implant, how its identity will be documented, the important limitations and how ongoing care can fit your life abroad. Informed value includes a practical long-term plan as well as the proposed change in appearance.

References

• Anvisa: device traceability labels and patient information
• Anvisa: Breast Implant Technovigilance Bulletin 03/2024, version 3
• US FDA: Risks and Complications of Breast Implants
• Silva et al.: Series of BIA-ALCL Cases in the Federal District, Brazil, RBCP 2025
• US FDA: Questions and Answers about BIA-ALCL
• INCA: Breast cancer information for the public